2. Signaling Pathways
  3. Immunology/Inflammation
  4. Complement System

Complement System

Complement System

Related Products

PDF 0.66 MB

The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.

The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-181040
    Factor B-IN-8
    		Inhibitor
    Factor B-IN-8 (Compound (3R ,4R )-15) is a potent, selective and orally active factor B inhibitor with an IC50 of 10.2 nM. Factor B-IN-8 can effectively inhibit the binding of factor B to C3b and the subsequent formation of C3 convertase (C3bBb). Factor B-IN-8 can inhibit the deposition of membrane attack complex (MAC) mediated by alternativepathway with an IC50 of 59.3 nM. Factor B-IN-8 can reduce the cleavage of factor B protein and decrease the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 can be used for researches of arthritis and paroxysmal nocturnal hemoglobinuria (PNH).
    Factor B-IN-8
  • HY-P11076
    CP-EPS8-NLS
    		Inhibitor
    CP-EPS8-NLS is a peptide with anti-AML property. CP-EPS8-NLS interferes with EPS8-associated signaling and exerts anti-AML activity in various AML cell types. CP-EPS8-NLS has potent antitumor activity in xenograft tumor models. CP-EPS8-NLS downregulates EPS8 expression and its downstream pathway.
    CP-EPS8-NLS
  • HY-P1345
    TLQP-21
    		Agonist
    TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca2+. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions.
    TLQP-21
  • HY-177123
    Refinicopan
    		Inhibitor
    Refinicopan is a complement factor D inhibitor with an IC50 of 10 nM. Refinicopan inhibits hemolysis of rabbit red blood cells. Refinicopan can be used to study diseases mediated by complement factor D.
    Refinicopan
  • HY-E70534
    C1s Proenzyme
    C1s Proenzyme, the native form of C1s enzyme, is an inactive zymogen until C1 is activated. C1 complex binds to and is activated by antigen-antibody complexes (immune complexes) yielding C1r enzyme. C1r enzyme in the C1 complex activates C1s proenzyme generating C1s enzyme.
    C1s Proenzyme
  • HY-P991796
    Anti-Mouse C5aR Antibody (20/70)
    		Inhibitor
    Anti-Mouse C5aR Antibody (20/70) reacts with mouse C5aR. Anti-Mouse C5aR Antibody (20/70) blocks C5aR both in vivo and in vitro. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).
    Anti-Mouse C5aR Antibody (20/70)
  • HY-130043
    11-O-Methylpseurotin A
    11-O-Methylpseurotin A is a compound of mixed polyketide synthase–nonribosomal peptide synthetase (PKS/NRPS) origin. 11-O-Methylpseurotin A selectively inhibits a Hof1 deletion strain.
    11-O-Methylpseurotin A
  • HY-P11647
    RPARPAR
    		Ligand
    RPARPAR is a CendR tumor-penetrating peptide. RPARPAR directly binds to the NRP-1 and NRP-2 receptors on the surface of tumor cells, triggering cellular internalization, vascular extravasation, and penetration into tumor tissues. RPARPAR serves as an efficient ligand for targeting nanocarriers to NRP-1-positive tumors. RPARPAR is applicable in research on tumor targeting and drug delivery.
    RPARPAR
  • HY-147586
    C5aR-IN-2
    C5aR-IN-2 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-2 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 49).
    C5aR-IN-2
  • HY-P1398A
    Compstatin control peptide TFA
    		Control
    Compstatin control peptide TFA is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor.
    Compstatin control peptide TFA
  • HY-W049802
    N-((Allyloxy)carbonyl)-N-methyl-L-alanine
    		Inhibitor
    N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative. N-((Allyloxy)carbonyl)-N-methyl-L-alanine can be used for the synthesis of inhibitors of complement factor D. Complement factor D inhibitors can be used in the research of immune system related disease.
    N-((Allyloxy)carbonyl)-N-methyl-L-alanine
  • HY-177611B
    Agazisiran sodium scrambled negative control
    		Inhibitor
    Agazisiran sodium scrambled negative control is the sequence scrambled negative control of Agazisiran sodium.
    Agazisiran sodium scrambled negative control
  • HY-E70533
    C1r Proenzyme
    C1r proenzyme, the native form of C1r enzyme, is an inactive zymogen until C1 is activated. C1r is activated when C1 binds to and is activated by antibodies bound to antigens (immune complexes) yielding C1r enzyme.
    C1r Proenzyme
  • HY-NP194A
    Cyclosporin A-OVA
    Cyclosporin A-OVA is a conjugate of Cyclosporin A (HY-B0579) and OVA. Cyclosporin A is an immunosuppressant which binds to the cyclophilin .
    Cyclosporin A-OVA
  • HY-147605
    Factor B-IN-3
    		Inhibitor
    Factor B-IN-3 (Example 3 target compound) is a potent complement factor B inhibitor. Factor B-IN-3 can be used for the research of diseases related to inflammation and immunity.
    Factor B-IN-3
  • HY-P991954
    GT103
    		Inhibitor
    GT103 is a human-derived monoclonal antibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer.
    GT103
  • HY-P991067
    Vensobafusp alfa
    		Inhibitor
    Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)..
    Vensobafusp alfa
  • HY-147604
    Factor B-IN-2
    		Inhibitor
    Factor B-IN-2 (Example 1 target compound) is a potent complement factor B inhibitor, with an IC50 of 1.5 μM. Factor B-IN-2 can be used for the research of diseases related to inflammation and immunity.
    Factor B-IN-2
  • HY-163062
    Tubulin/NRP1-IN-1
    		Inhibitor
    Tubulin/NRP1-IN-1 (compound TN-2) is a dual inhibitor of Tubulin and NRP1 with IC50s of 0.71 and 0.85 μM, respectively. Tubulin/NRP1-IN-1 significantly inhibits the viability of prostate tumor cell lines and induces apoptosis.
    Tubulin/NRP1-IN-1
  • HY-177621A
    Cevolisiran sodium
    		Inhibitor
    Cevolisiran sodium, a siRNA, is a complement component 3 (C3) synthesis reducer.
    Cevolisiran sodium
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity